# NCT05652686 (NCT05652686)

> A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05652686
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Phanes Therapeutics
- Conditions: Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Interventions: Peluntamig (PT217); Carboplatin + Etoposide; Paclitaxel.; Atezolizumab; Lurbinectedin; Irinotecan (drug); Topotecan
- Enrollment: 203
- Primary outcome: To determine recommended dose for expansion (RDE) of Peluntamig (PT217).
- Primary outcome: To evaluate the safety and tolerability of Peluntamig (PT217).
- Primary outcome: To evaluate the efficacy of Peluntamig (PT217) monotherapy or in combination treatments as assessed by ORR.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05652686